AtriCure to Present at the Canaccord Genuity 38th Annual Growth Conference
July 16 2018 - 8:00AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
(LAA) management, today announced that it will present at the
Canaccord Genuity 38th Annual Growth Conference at the
Intercontinental Hotel in Boston on Thursday, August 9, 2018.
Management is scheduled to present at 12:00 p.m. Eastern Time.
A live audio webcast of the presentation may be accessed by
visiting the Investors page of AtriCure’s corporate website at
ir.atricure.com. A replay of the presentation will be available for
90 days following the presentation.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first and only
medical device to receive FDA approval for the treatment of
persistent Afib. AtriCure’s AtriClip Left Atrial Appendage
Exclusion System products are the most widely sold LAA management
devices worldwide, with more than 125,000 implanted to date. For
more information, visit AtriCure.com or follow us on Twitter
@AtriCure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180716005037/en/
AtriCure, Inc.Andy Wade, 513-755-4564Senior Vice President and
Chief Financial Officerawade@atricure.comorGilmartin GroupLynn
Pieper Lewis, 415-937-5402Investor
Relationslynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Aug 2024 to Sep 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Sep 2023 to Sep 2024